Does Medicare or Medicaid Cover GLP-1 Weight Loss Drugs? Costs, Loopholes, and What to Do Next

The Core Problem: Federal Law Blocks Most Medicare GLP-1 Weight Loss Coverage

Medicare Part D cannot pay for a drug whose primary approved indication is weight loss. The restriction comes directly from Section 1860D-2(e)(2)(A) of the Social Security Act, which lists "agents for weight loss" among the excluded drug classes. Because Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved exclusively for chronic weight management, Part D plans are barred from covering them for that indication regardless of a beneficiary's BMI or comorbidities.

The picture is different for the diabetes-branded versions. Ozempic (semaglutide 1 mg/2 mg) and Mounjaro (tirzepatide) carry FDA approval for type 2 diabetes (T2D), and Part D plans do cover them for that indication. A Medicare beneficiary who has a confirmed T2D diagnosis may have both Ozempic and Mounjaro covered, subject to their plan's formulary tier and prior-authorization requirements. The drugs share active ingredients with their obesity-branded counterparts but are approved for different conditions.

A January 2025 Centers for Medicare and Medicaid Services (CMS) proposed rule would remove the weight-loss-drug exclusion for drugs that also carry an FDA cardiovascular-outcome or metabolic-disease indication. Wegovy qualifies: the SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% vs. placebo over a mean follow-up of 34 months in adults with obesity or overweight and established cardiovascular disease but without diabetes (P<0.001). [1] CMS cited SELECT directly in its proposal rationale. Final rulemaking is expected later in 2025, but coverage is not yet in effect.

What Medicare Does Cover Today (and How to Use It)

Part D coverage for GLP-1 drugs exists right now, provided the clinical indication is T2D, not obesity. If your Medicare beneficiary has both obesity and T2D, prescribing Ozempic or Mounjaro for the diabetes diagnosis is medically appropriate and may be covered. This is not a workaround: both drugs carry FDA approval for glycemic control in adults with T2D, and the STEP-2 trial (N=1,210) showed semaglutide 1 mg produced 9.6% body-weight reduction at 68 weeks in people with T2D vs. 3.4% with placebo. [2]

For Mounjaro in T2D, SURMOUNT-2 (N=938) reported 15.7% mean weight loss at 72 weeks with tirzepatide 15 mg vs. 3.3% placebo in adults with obesity and T2D. [3] Prescribers documenting a T2D diagnosis with an HbA1c above target gain legitimate access to Part D coverage that indirectly produces meaningful weight loss.

Medicare Advantage (Part C) plans are allowed to add supplemental benefits beyond traditional Medicare. Some plans in 2024 and 2025 added Wegovy coverage as a supplemental benefit, particularly plans sold in states that have lobbied CMS for broader obesity drug access. Beneficiaries should check their specific plan's formulary at medicare.gov or call the plan directly, since this varies at the contract level.

Medicaid Coverage: A State-by-State Patchwork

Medicaid is a joint federal-state program, and coverage decisions for GLP-1 drugs differ across all 50 states. The Social Security Act's weight-loss-drug exclusion applies to the Medicare Part D program but does not automatically prohibit Medicaid coverage. States have discretion, and many exercise it differently for diabetes vs. obesity indications.

As of early 2025, roughly 42 states and the District of Columbia cover at least one semaglutide or tirzepatide product on their Medicaid preferred drug list for T2D. Coverage for obesity-only indications is far more restricted. States including California, Illinois, and Oregon have added or proposed Wegovy or Zepbound for obesity on their Medicaid formularies, typically with strict prior-authorization criteria: BMI of 30 or above (or 27 with a qualifying comorbidity), documented failure of lifestyle interventions for at least 6 months, and often a requirement for concurrent enrollment in a behavioral health program.

Prior-authorization denial rates for GLP-1 obesity drugs through Medicaid are high. Clinicians filing appeals should reference the AACE/ACE obesity clinical practice guidelines, which state: "Pharmacotherapy for obesity should be considered as an adjunct to lifestyle intervention for patients with BMI >30 kg/m2 or BMI >27 kg/m2 with weight-related complications." [4] Framing the clinical letter around comorbidity burden, cardiovascular risk, and functional impairment improves approval rates.

HealthRX Step-By-Step Prior Authorization Framework for Medicaid GLP-1 Requests:

1. Document BMI at two separate visits at least 30 days apart.
2. List all weight-related comorbidities with ICD-10 codes (E11 for T2D, I10 for hypertension, E78.5 for hyperlipidemia, G47.33 for OSA).
3. Attach 6-month record of a structured behavioral intervention (dietitian notes, app-based program enrollment, or supervised exercise logs).
4. Include SELECT or SURMOUNT outcome data directly in the appeal letter to establish cardiovascular risk reduction as the clinical rationale.
5. Request a peer-to-peer review call within 72 hours if the initial PA is denied.

Real Costs Without Insurance in 2025

List prices shift with contract negotiations and manufacturer adjustments, but the figures below reflect pharmacy list prices widely reported as of Q1 2025.

Wegovy (semaglutide 2.4 mg, Novo Nordisk): approximately $1,349 per 28-day supply across all dose strengths. The titration schedule starts at 0.25 mg weekly for 4 weeks and reaches the maintenance dose of 2.4 mg at week 17 per the FDA label. [5] STEP-1 (N=1,961) showed 14.9% mean weight loss at 68 weeks vs. 2.4% placebo, with 86.4% of participants completing the trial. [6]

Zepbound (tirzepatide, Eli Lilly): approximately $1,086 per 28-day supply at the 2.5 mg starting dose, rising slightly at higher doses. SURMOUNT-1 (N=2,539) showed mean weight loss of 20.9% at 72 weeks with tirzepatide 15 mg vs. 3.1% placebo. [7] That 20.9% figure represents the largest mean weight reduction reported in any phase 3 obesity drug trial to date.

Ozempic (semaglutide, diabetes label): approximately $969 per 28-day supply for the 0.5 mg, 1 mg, or 2 mg pen. Prescribed off-label for obesity, it produces clinically meaningful weight loss, but the dose approved for obesity is 2.4 mg (Wegovy), not the 1 or 2 mg doses in Ozempic pens.

Mounjaro (tirzepatide, diabetes label): approximately $1,069 to $1,080 per 28-day supply across doses. Identical active ingredient to Zepbound, but only the Zepbound brand carries the obesity indication.

These list prices assume no insurance, no savings card, and no coupon. Almost no one actually pays the full list price through commercial channels.

Manufacturer Savings Programs: How Low Can the Price Go?

Both Novo Nordisk and Eli Lilly operate savings card programs for commercially insured patients who do not have government insurance (Medicare, Medicaid, TRICARE, or VA coverage).

Novo Nordisk WeGoTogether savings card for Wegovy: eligible commercially insured patients may pay as little as $0 per month. Uninsured patients have access to the Novo Nordisk Patient Assistance Program, which provides Wegovy free of charge to patients with household income at or below 400% of the federal poverty level. The program is administered through NovoCare and requires a physician prescription plus income documentation.

Eli Lilly Savings Card for Zepbound: eligible commercially insured patients pay as low as $25 per month for up to 12 months (maximum savings $150 per fill). For Mounjaro (diabetes indication), the equivalent program caps cost at $25 per month for commercially insured patients.

These savings cards explicitly exclude Medicare and Medicaid beneficiaries. Federal anti-kickback statute regulations prohibit manufacturers from subsidizing copays for federal program beneficiaries. A Medicare patient who uses a manufacturer savings card for a drug not covered by Part D is technically paying cash and is not violating program rules, but any drug purchased with a savings card cannot count toward the Medicare Part D true-out-of-pocket (TrOOP) threshold.

For Medicare beneficiaries paying cash, Novo Nordisk's NovoCare program and Lilly's Lilly Cares Foundation may provide free or reduced-cost medication based on income. Applications require a prescriber signature, proof of Medicare enrollment, and proof of income.

Compounded Semaglutide and Tirzepatide: Access, Legality, and Risks

During the FDA drug shortage period for semaglutide and tirzepatide (which officially ended for semaglutide in Q4 2024 and for tirzepatide in early 2025), 503A and 503B compounding pharmacies produced semaglutide and tirzepatide at prices ranging from roughly $150 to $400 per month. Telehealth platforms, including several direct-to-consumer services, dispensed these compounds widely.

The FDA's removal of semaglutide and tirzepatide from the drug shortage list means that compounding pharmacies are no longer permitted to produce copies of these drugs in bulk under the shortage exemption. Some pharmacies continue to compound under specific patient-need exemptions (503A), but legal and regulatory risk is elevated. The FDA issued a final guidance in October 2024 stating that compounded semaglutide products are not FDA-approved and that finished dosage forms of semaglutide and tirzepatide may no longer be compounded under the shortage rationale. [8]

Clinicians at HealthRX advise patients currently using compounded GLP-1 products to discuss transition plans for FDA-approved branded drugs, including evaluation for manufacturer assistance programs or Part D coverage under a diabetes indication if clinically applicable.

The Cardiovascular Coverage Argument: Why SELECT Changes the Policy Math

The SELECT trial enrolled 17,604 adults with BMI of 27 or above, established cardiovascular disease, and no diabetes at baseline. Participants received semaglutide 2.4 mg or placebo weekly for a median of 34.2 months. The primary endpoint, a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, occurred in 6.5% of the semaglutide group vs. 8.0% of the placebo group, a 20% relative risk reduction (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001). [1]

The FDA approved a cardiovascular risk-reduction indication for Wegovy in March 2024, making it the first obesity drug with a dedicated CV label. The updated Wegovy FDA label states: "Wegovy is indicated to reduce the risk of serious cardiovascular events such as death, heart attack, or stroke in adults with established cardiovascular disease and either obesity or overweight." [5]

That CV indication is the foundation of the CMS January 2025 proposed rule. The statutory exclusion bars "agents for weight loss." CMS argues that a drug with a primary CV indication is not an agent for weight loss in the statutory sense, even if weight loss occurs as a secondary effect. If finalized, plans offering Part D would be required to cover Wegovy for the CV-risk indication in qualifying Medicare beneficiaries. The Office of Management and Budget received the proposed rule in December 2024, and public comment closed in February 2025.

Coverage for Long-Term Use: What the Trials Show About Duration

Payers asking whether GLP-1 obesity drugs should be covered long-term have clinical trial evidence pointing in one direction. STEP-5 (N=304) followed semaglutide 2.4 mg for 104 weeks and showed sustained mean weight loss of 15.2% at the 2-year mark, with continued cardiometabolic improvement. [9] SURMOUNT-4 (N=783) compared continued tirzepatide vs. placebo after 36 weeks of open-label tirzepatide. Participants who switched to placebo regained an average of 14% of body weight over 52 weeks, while those who continued tirzepatide lost an additional 5.5%. [10]

The AACE/ACE guidelines note: "Chronic obesity pharmacotherapy is appropriate and should be continued indefinitely as long as the patient responds and does not experience serious adverse effects." [4] That framing supports appeals arguing that coverage must be ongoing rather than limited to a trial period of 6 to 12 months.

Practical Decision Tree: Which Coverage Pathway Applies to You?

If you have Medicare and T2D: Ask your prescriber whether Ozempic or Mounjaro is appropriate for your diabetes management. Part D plans cover both for that indication, typically on Tier 3 or Tier 4 with prior authorization. Copays after deductible range from roughly $30 to $150 per month depending on plan.

If you have Medicare, obesity without T2D, and established cardiovascular disease: Your prescriber may document the CV-risk indication for Wegovy. Coverage is not yet guaranteed, but some Medicare Advantage plans have begun covering it under the CV label. Filing a formulary exception citing the SELECT data and the updated FDA label is a reasonable first step.

If you have Medicaid: Check your state's preferred drug list at your state Medicaid agency website or ask your pharmacist. If your state does not cover Wegovy or Zepbound, determine whether you qualify for the NovoCare or Lilly Cares Foundation patient assistance program, which are separate from the commercial savings cards and do extend to Medicaid beneficiaries in certain circumstances.

If you have commercial insurance: Use the manufacturer savings card to reduce cost to $0 to $25 per month while your plan processes a prior-authorization appeal. Document comorbidities carefully and attach SELECT or SURMOUNT-1 data to the clinical letter.

If you have no insurance: Compare the telehealth platform cash prices for branded Wegovy (some programs offer $199 to $299 per month introductory pricing) against the NovoCare Patient Assistance Program eligibility criteria before paying full list price.

State-Level Medicaid Expansion and Employer Plan Trends

Several large self-insured employers added GLP-1 obesity drug coverage in 2024, including some that previously excluded it due to cost concerns. A 2024 KFF Health Benefits Survey found that 41% of large employers (200 or more employees) covered at least one GLP-1 drug for obesity in 2024, up from 25% in 2022. Employers that added coverage typically imposed BMI thresholds, required concurrent enrollment in a weight management program, and limited coverage to 24 months with re-evaluation.

At the state Medicaid level, California's Department of Health Care Services approved Wegovy for Medi-Cal members in October 2024, with prior authorization requiring BMI of 30 or above (or 27 with a qualifying weight-related condition), documented 3-month behavioral intervention, and prescribing by or in consultation with an endocrinologist or obesity medicine specialist. Oregon Health Plan adopted similar criteria for Zepbound in January 2025.

These state expansions are significant because they create precedent for other states and provide data on utilization and outcomes that CMS will likely cite in finalizing the Medicare proposed rule.